*Department of Radiation Oncology, Henry Ford Cancer Institute

‡Department of Women’s Health Services, Division of Gynecologic Oncology, Henry Ford Cancer Institute, Detroit, MI

†Clinical Oncology Department, University of Alexandria Faculty of Medicine, Alexandria, Egypt

Conceptualization and data collection and organization: M.A.E. and A.I.G. Data analysis: C.B. and A.I.G. Methodology: A.I.G., M.A.E., and M.H. Writing—original draft: A.I.G., M.E., and A.B. Writing—review and editing: M.A.E., M.H., A.B., and A.I.G.

The results of this study were presented in part at the 64th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in San Antonio, TX, from October 23-26, 2022 (Abstract ID 2605) https://doi.org/10.1016/j.ijrobp.2022.07.1277.

The authors declare no conflicts of interest.

Correspondence: Mohamed A. Elshaikh, MD, Department of Radiation Oncology, Henry Ford Cancer Institute, 2800 W. Grand Boulevard, Detroit, MI 48202. E-mail: [email protected].